Molecular testing for activating BRAF variants has become standard of care as recommended by NCCN and the European Society for Medical Oncology (ESMO) for stage III or IV melanoma, to evaluate the eligibility and efficacy of BRAF/MEK inhibitors targeting the BRAF-MEK-ERK pathway (7). The gene discussed is MAP2K7; the disease is melanoma.